Trials / Not Yet Recruiting
Not Yet RecruitingNCT06694298
A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus
A Phase I Clinical Study of BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection in Refractory Active Systemic Lupus Erythematosus Patients
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to observe the safety and tolerability of SYS6020 in adult participants with refractory active systemic lupus erythematosus, determine the recommended dose (RD) that may be explored for subsequent studies, and preliminly evaluate the clinical efficacy of this product,and explore the pharmacokinetics and immunogenicity of SYS6020 injection in those participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYS6020 | BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion |
Timeline
- Start date
- 2024-12-26
- Primary completion
- 2029-01-29
- Completion
- 2029-01-29
- First posted
- 2024-11-19
- Last updated
- 2024-11-19
Source: ClinicalTrials.gov record NCT06694298. Inclusion in this directory is not an endorsement.